{"contentid": 488513, "importid": NaN, "name": "AbbVie's shares rise as 1st-qtr financials beat expectations", "introduction": "US drugmaker AbbVie's shares rose as much as 2% pre-market today, after it announced financial results for the first quarter 2021 that beat expectations and saw a massive jump in pharmaceutical revenue for the reporting period.", "content": "<p>US drugmaker AbbVie&rsquo;s (NYSE: ABBV) shares rose as much as 2% pre-market today, after it announced financial results for the first quarter 2021 that beat expectations and saw a massive jump in pharmaceutical revenue for the reporting period.</p>\n<p>The company generated $13.0 billion in revenue for the quarter in 2021, up 51% from $8.6 billion in the same quarter in 2020, and beating the FactSet consensus was $12.7 billion.&nbsp;</p>\n<p>AbbVie's adjusted earnings per share (EPS) for the quarter were $2.95, against a FactSet consensus of $2.81.&nbsp;</p>\n<p>AbbVie is raising its generally accepted accounting principles (GAAP) diluted EPS guidance for the full-year 2021 from $6.69 to $6.89 to $7.27 to $7.47. It is lifting its adjusted diluted EPS for the full-year 2021 from $12.32 to&nbsp;$12.52&nbsp;to&nbsp;$12.37&nbsp;to&nbsp;$12.57.&nbsp;</p>\n<p>\"We are off to an excellent start to 2021, with strong performance across our core therapeutic areas and first quarter revenue and earnings results ahead of our expectations,\" said Richard Gonzalez, chairman and chief executive of AbbVie. \"Our new products are delivering impressive performance and we are on the cusp of potential commercial approvals for more than a dozen new products or indications over the next two years &ndash; including five expected approvals in 2021,\" he noted.</p>\n<h2><strong>Select product performances</strong></h2>\n<p>Humira (adalimumab) sales rose 3.5% to $4.87 billion, beating expectations of $4.78 billion. Sales, however, fell 8.3% in markets outside the USA due to rising biosimilar competition, especially in Europe.</p>\n<p>Sales of Skyrizi (risankizumab) surged about 91% to $574 million in the first quarter, beating estimates of $569.89 million, according to IBES data from Refinitiv.</p>\n<p>Global Rinvoq (upadacitinib) net revenues were&nbsp;$303 million.</p>\n<p>Sales of blood cancer drug Imbruvica (ibrutinib) were $1.27 billion, up 2.9%.</p>\n<p>Sales of hepatitis C virus drug Mavyret (glecaprevir/pibrentasvir) were $415 million, down 25.7%.</p>\n<p>Sales of Botox (onabotulinumtoxinA), which AbbVie gained through its $63 billion acquisition of Allergan, rose 44.7% to $447 million as a treatment for wrinkles and other cosmetic uses, and the drug generated sales of $532 million, up 7%, as a treatment for conditions such as migraine.</p>", "date": "2021-04-30 16:31:00", "meta_title": "AbbVie's shares rise as 1st-qtr financials beat expectations", "meta_keywords": "AbbVie, Financial results, First-quarter, 2021, Humira, Skyrizi, Botox", "meta_description": "AbbVie's shares rise as 1st-qtr financials beat expectations", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-30 16:29:50", "updated": "2021-04-30 16:39:49", "access": NaN, "url": "https://www.thepharmaletter.com/article/abbvie-s-shares-rise-as-1st-qtr-financials-beat-expectations", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "abbvie_sign.jpg", "image2id": "abbvie_sign_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Anti-Arthritics/Rheumatics, Anti-virals, Inflammatory diseases, Oncology", "topic_tag": "Financial", "geography_tag": "USA", "company_tag": "AbbVie, Allergan", "drug_tag": "Botox, Humira, Imbruvica, Mavyret, Rinvoq, Skyrizi", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-30 16:31:00"}